FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2746753615> ?p ?o ?g. }

• W2746753615 endingPage "3346" @default.
• W2746753615 startingPage "3338" @default.
• W2746753615 abstract "Purpose The objectives were to evaluate dosing schedules of labetuzumab govitecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for tumor delivery of 7-ethyl-10-hydroxycamptothecin (SN-38), in an expanded phase II trial of patients with relapsed or refractory metastatic colorectal cancer. Patients and Methods Eligible patients with at least one prior irinotecan-containing therapy received labetuzumab govitecan once weekly at 8 and 10 mg/kg, or two times per week at 4 and 6 mg/km on weeks 1 and 2 of 3-week repeated cycles. End points were safety, response, pharmacokinetics, and immunogenicity. Results Eighty-six patients who had undergone a median of five prior therapies (range, one to 13) were each enrolled into one of the four cohorts. On the basis of Response Evaluation Criteria in Solid Tumors 1.1, 38% of these patients had a tumor as well as plasma carcinoembryonic antigen reduction from baseline after labetuzumab govitecan treatment; one patient achieved a partial response with a sustained response spanning > 2 years, whereas 42 patients had stable disease as the best overall response. Median progression-free survival and overall survival were 3.6 and 6.9 months, respectively. The major toxicities (grade ≥ 3) among all cohorts were neutropenia (16%), leukopenia (11%), anemia (9%), and diarrhea (7%). The antibody-drug conjugate’s mean half-life was 16.5 hours for the four cohorts. Anti-drug/anti-antibody antibodies were not detected. The two once-weekly dose schedules, showing comparable toxicity and efficacy, were chosen for further study. Conclusion Monotherapy with labetuzumab govitecan demonstrated a manageable safety profile and therapeutic activity in heavily pretreated patients with metastatic colorectal cancer, all with prior irinotecan therapy. Further studies of labetuzumab govitecan treatment alone or in combination with other therapies in earlier settings are indicated." @default.
• W2746753615 created "2017-08-31" @default.
• W2746753615 creator A5003890903 @default.
• W2746753615 creator A5012289008 @default.
• W2746753615 creator A5013142527 @default.
• W2746753615 creator A5014083764 @default.
• W2746753615 creator A5039492614 @default.
• W2746753615 creator A5043569662 @default.
• W2746753615 creator A5044055404 @default.
• W2746753615 creator A5058973864 @default.
• W2746753615 creator A5061373605 @default.
• W2746753615 creator A5065431287 @default.
• W2746753615 creator A5066052401 @default.
• W2746753615 creator A5071328253 @default.
• W2746753615 creator A5072144086 @default.
• W2746753615 creator A5078259926 @default.
• W2746753615 creator A5080788977 @default.
• W2746753615 date "2017-10-10" @default.
• W2746753615 modified "2023-10-01" @default.
• W2746753615 title "Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer" @default.
• W2746753615 cites W1271574226 @default.
• W2746753615 cites W1486001319 @default.
• W2746753615 cites W1487353108 @default.
• W2746753615 cites W1516980941 @default.
• W2746753615 cites W1905765735 @default.
• W2746753615 cites W1965278354 @default.
• W2746753615 cites W1968592882 @default.
• W2746753615 cites W1979685373 @default.
• W2746753615 cites W1990303005 @default.
• W2746753615 cites W2002815766 @default.
• W2746753615 cites W2005684277 @default.
• W2746753615 cites W2018988859 @default.
• W2746753615 cites W2019607817 @default.
• W2746753615 cites W2025762172 @default.
• W2746753615 cites W2030692610 @default.
• W2746753615 cites W2061537048 @default.
• W2746753615 cites W2099808918 @default.
• W2746753615 cites W2101501196 @default.
• W2746753615 cites W2103502575 @default.
• W2746753615 cites W2103789431 @default.
• W2746753615 cites W2107587681 @default.
• W2746753615 cites W2112245386 @default.
• W2746753615 cites W2118644245 @default.
• W2746753615 cites W2119347977 @default.
• W2746753615 cites W2125060052 @default.
• W2746753615 cites W2133792756 @default.
• W2746753615 cites W2140261207 @default.
• W2746753615 cites W2147834058 @default.
• W2746753615 cites W2231446168 @default.
• W2746753615 cites W2248346391 @default.
• W2746753615 cites W2280885574 @default.
• W2746753615 cites W2534417440 @default.
• W2746753615 cites W2566164050 @default.
• W2746753615 cites W2570618306 @default.
• W2746753615 cites W2597045666 @default.
• W2746753615 doi "https://doi.org/10.1200/jco.2017.73.9011" @default.
• W2746753615 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8259133" @default.
• W2746753615 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28817371" @default.
• W2746753615 hasPublicationYear "2017" @default.
• W2746753615 type Work @default.
• W2746753615 sameAs 2746753615 @default.
• W2746753615 citedByCount "64" @default.
• W2746753615 countsByYear W27467536152017 @default.
• W2746753615 countsByYear W27467536152018 @default.
• W2746753615 countsByYear W27467536152019 @default.
• W2746753615 countsByYear W27467536152020 @default.
• W2746753615 countsByYear W27467536152021 @default.
• W2746753615 countsByYear W27467536152022 @default.
• W2746753615 countsByYear W27467536152023 @default.
• W2746753615 crossrefType "journal-article" @default.
• W2746753615 hasAuthorship W2746753615A5003890903 @default.
• W2746753615 hasAuthorship W2746753615A5012289008 @default.
• W2746753615 hasAuthorship W2746753615A5013142527 @default.
• W2746753615 hasAuthorship W2746753615A5014083764 @default.
• W2746753615 hasAuthorship W2746753615A5039492614 @default.
• W2746753615 hasAuthorship W2746753615A5043569662 @default.
• W2746753615 hasAuthorship W2746753615A5044055404 @default.
• W2746753615 hasAuthorship W2746753615A5058973864 @default.
• W2746753615 hasAuthorship W2746753615A5061373605 @default.
• W2746753615 hasAuthorship W2746753615A5065431287 @default.
• W2746753615 hasAuthorship W2746753615A5066052401 @default.
• W2746753615 hasAuthorship W2746753615A5071328253 @default.
• W2746753615 hasAuthorship W2746753615A5072144086 @default.
• W2746753615 hasAuthorship W2746753615A5078259926 @default.
• W2746753615 hasAuthorship W2746753615A5080788977 @default.
• W2746753615 hasBestOaLocation W27467536152 @default.
• W2746753615 hasConcept C112705442 @default.
• W2746753615 hasConcept C121332964 @default.
• W2746753615 hasConcept C121608353 @default.
• W2746753615 hasConcept C126322002 @default.
• W2746753615 hasConcept C142424586 @default.
• W2746753615 hasConcept C143998085 @default.
• W2746753615 hasConcept C159654299 @default.
• W2746753615 hasConcept C203014093 @default.
• W2746753615 hasConcept C2777063308 @default.
• W2746753615 hasConcept C2777387746 @default.
• W2746753615 hasConcept C2778248108 @default.
• W2746753615 hasConcept C2780259306 @default.

• next